FMS, COO, RMD, THC And HCA, Pushing Health Services Industry Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 79 points (0.5%) at 15,295 as of Wednesday, May 15, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,703 issues advancing vs. 1,237 declining with 128 unchanged.

The Health Services industry currently sits up 0.1% versus the S&P 500, which is up 0.6%. A company within the industry that fell today was Covidien ( COV), up 0.51. Top gainers within the industry include Boston Scientific ( BSX), up 3.5%, Abbott Laboratories ( ABT), up 1.6%, Smith & Nephew ( SNN), up 1.4%, Laboratory Corporation of America Holdings ( LH), up 1.4% and Catamaran ( CTRX), up 1.3%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is down $0.74 (-2.1%) to $33.72 on heavy volume Thus far, 407,481 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 162,600 shares. The stock has ranged in price between $33.59-$33.76 after having opened the day at $33.68 as compared to the previous trading day's close of $34.46.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $10.6 billion and is part of the health care sector. The company has a P/E ratio of 18.2, above the S&P 500 P/E ratio of 17.7. Shares are up 0.5% year to date as of the close of trading on Tuesday.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Mining and Resources Lead Europe's Benchmarks Lower

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Here's What's Boosting European Benchmarks

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space